Piracetam in elderly psychiatric patients with mild diffuse cerebral impairment

  title={Piracetam in elderly psychiatric patients with mild diffuse cerebral impairment},
  author={Guy Chouinard and Lawrence. Annable and Andr{\'e}e Ross-Chouinard and Madeleen Olivier and F Fontaine},
In a 12-week double-blind study, piracetam at two dose levels (2.4 and 4.8g/day) was compared to placebo in the treatment of 60 elderly psychiatric patients with mild diffuse cerebral impairment, but no signs of focal brain lesion. The psychiatric illness, schizophrenia or affective disorder, of patients selected was in remission at the time of the study. Monthly evaluations by the nurse revealed that piracetam improved overall functioning, particularly alertness, socialization, and cooperation… Expand
Clinical Efficacy of Piracetam in Cognitive Impairment: A Meta-Analysis
The results of this analysis provide compelling evidence for the global efficacy of piracetam in a diverse group of older subjects with cognitive impairment. Expand
Does the Addition of Piracetam Safely and Effectively Improve Behavioral and or Cognitive Functions in Schizophrenia
There requires a continued and more updated investigation to be aimed at determining a specific dose of piracetam therapy, a specific patient population for which Piracetam is most effective and to further elaborate its safety profile outside a controlled research setting. Expand
Antipsychotic medication for elderly people with schizophrenia.
Antipsychotics may be widely used in the treatment of elderly people with schizophrenia, however, based on this systematic review, there is little robust data available to guide the clinician with respect to the most appropriate drug to prescribe. Expand
Piracetam: a review of pharmacological properties and clinical uses.
  • B. Winblad
  • Psychology, Medicine
  • CNS drug reviews
  • 2005
Piracetam, a derivative of the neurotransmitter gamma-aminobutyric acid (GABA), has a variety of physiological effects that may result from the restoration of cell membrane fluidity, and its efficacy is documented in cognitive disorders and dementia, vertigo, cortical myoclonus, dyslexia, and sickle cell anemia. Expand
Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia
Present evidence suggests some therapeutic efficacy for nootropics and metabolically active compounds as well as alkylxanthines in the treatment of dementia. Expand
Recent uses of piracetam in pediatric neurology
Aamir Jalal Al Mosawi Advisor in Pediatrics and Pediatric Psychiatry Children, Teaching Hospital of Baghdad Medical City Head, Iraq Headquarter of Copernicus Scientists International Panel Baghdad,Expand
Peptide analogs of pyracetam as ligands for hypothetical nootropic receptors
Pyracetam (N-carbamoylmethylbutyrolactam (I)) is the first representative of nootropic agents, a novel class of psychotropic drugs [18]. Nootropic agents are generally accepted as being drugs whichExpand
Effects of four non-cholinergic cognitive enhancers in comparison with tacrine and galanthamine on scopolamine-induced amnesia in rats
Four so-called cognitive enhancers, all widely used for the treatment of the symptoms associated with mental aging, cerebral insufficiency and senile memory disorder, were investigated in this passive avoidance paradigm and Piracetam, an extract of Ginkgo biloba, dihydroergocristine and a combination of raubasine with dihydromine, all attenuated the amnesia induced by scopolamine. Expand
Recent Uses of Piracetam in Pediatric Neurology.
Abstract Piracetam (2-oxo-1-pyrrolidine acetamide) is a cyclical derivative of GABA (gamma-aminobutyric acid). It was first synthesized during the 1950s by Corneliu E. Giurgea. There are reports ofExpand
Elevated corticosteroid levels block the memory-improving effects of nootropics and cholinomimetics
In the light of new observations showing increased cortisol concentrations in Alzheimer patients, this steroid dependency of the effects of memory enhancers might explain why only a limited number of these patients respond to therapy with nootropics or cholinomimetics. Expand


Effects of piracetam on regional cerebral blood flow and mental functions in patients with organic dementia
The effects of piracetam (Nootropil®, UCB 6215) on mental functions and on regional cerebral blood flow (rCBF) were investigated in eight patients in the presenile age who displayed symptoms ofExpand
Piracetam in chronic brain failure.
A double-blind, placebo-controlled trial was carried out on 109 aged patients with minimal or with moderate chronic brain failure to assess the effectiveness of piracetam in preventing the progression of dementia, and the findings do not support the usefulness of pir acetam in the treatment of such patients. Expand
Piracetam in the treatment of post-concussional syndrome. A double-blind study.
In the author's opinion, piracetam seems to be a promising new drug for the treatment of post-concussional syndrome. Expand
A double blind investigation of piracetam (Nootropil) vs placebo in geriatric memory.
Fifty-six hospitalized geriatric patients between the ages of 65 and 80 were given piracetam (Nootropil) 2400 mg/day or placebo on a double blind basis over a two month period and there were no significant statistical differences. Expand
[Piracetam and vigilance. A study of EEG changes and clinical effects in gerontopsychiatric patients (author's transl)].
The statistical analysis of the resulting factor scores shows that piracetam induces significant EEG changes: decrease of slow frequencies, augmentation and acceleration of alpha-activity and increase of beta-activity, indicating an increase in vigilance. Expand
Some effects of piracetam (UCB 6215 nootropyl) on chronic schizophrenia
Some cognitive improvement but little if any change in the disease state of the patient is suggested by a study of effects of a nootropic drug on chronic schizophrenia. Expand
Antipsychotic Drugs
The term psychosis refers to a variety of mental disorders characterized by one or more of the following symptoms: diminished and distorted capacity to process information and draw logicalExpand
A double-blind study on the effects of piracetam upon perceptual and psychomotor performance at varied heart rates in patients treated with artificial pacemakers
Results indicate that Piracetam had some protective effect against the influence of an assumed cerebral hypoxia at the lower rate or a cortical arousing effect, which counteracted the decrement in vigilance associated with the slow heart rate. Expand
In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients, found to be equally effective in controlling parkinsonian symptoms and as efficacious as procyclidine, their previous antiparkinsonian drug. Expand
Effect of piracetam on EEG spectra of boys with learning disorders
Power spectral analyses revealed that piracetam caused a decrease in the amount of delta activity and an increase in the average EEG frequency, which is in agreement with those obtained by other workers in adult patients. Expand